Real-World Treatment and Outcomes for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer Following Pembrolizumab Availability in Australia
Clinical Colorectal Cancer · 2026-09
DOI: 10.1016/j.clcc.2026.09.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2026-09. Verfasst von Grace Y Kim und 22 weiteren Autor:innen. Beteiligte Einrichtung: Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Oncology, …. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Merck Sharp & Dohme (Australia) Pty Limited, MSD.
Abstract (Originalsprache)
INTRODUCTION: The 5-year follow-up results of KEYNOTE-177 established pembrolizumab as a standard first-line (1L) treatment for deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC), demonstrating improved response rates, progression-free survival (PFS), and tolerability over chemotherapy. Pembrolizumab became available as a 1L option in Australia following government reimbursement in August 2021. Real-world treatment patterns and outcomes in Australia since then have not previously been reported. PATIENTS AND METHODS: Patients with dMMR mCRC diagnosed from August 1, 2021 to May 30, 2025, were analyzed using data from Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) and TRACC-SELECT, Australian multi-site prospective registries. Clinicopathologic characteristics, treatment patterns, and outcomes were examined. Survival outcomes for 1L pembrolizumab-treated patients were analyzed using Kaplan-Meier. RESULTS: From 36 sites, 120 dMMR mCRC patients were identified; 109 (91%) received systemic treatment. 1L treatment included pembrolizumab (n = 103, 94%), clinical trial enrolment (n = 4, 4%), and chemotherapy (n = 2, 2%). Among pembrolizumab-treated patients, median age was 75 years, 49% had a BRAFV600E mutation, and 17% had an Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2. Median follow-up was 25.8 months. The real-world objective response rate was 58%, while 17% had progressive disease as best response. Median duration of therapy was 15.2 months. Of 74 patients who discontinued pembrolizumab, 21 (28%) completed the 2-year course, 28 (38%) discontinued due to progressive disease, 11 (15%) due to toxicity, 6 (8%) after achieving complete response before 2 years, and 8 (11%) for other reasons. Median PFS was 37.9 months. Median overall survival (OS) was not reached; 12- and 24-month OS rates were 88% and 77%, respectively. CONCLUSION: This real-world cohort included older patients with higher rates of BRAFV600E mutation and poorer ECOG PS than KEYNOTE-177. There has been rapid and wide uptake of pembrolizumab as a new standard of care, with promising outcomes. Ongoing data collection and analyses will evaluate predictors of immunotherapy response and real-world second-line treatment patterns and outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Oncology, Western Health, Footscray, Victoria, Australia. Electronic address: ki…
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Oncology, Western Health, Footscray, Victoria, Australia; Department of Medical…
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Oncology, Western Health, Footscray, Victoria, Australia.
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; Departm…
- Department of Medical Oncology, Eastern Health, Box Hill, Victoria, Australia; Department of Medicine, Nursing and Health Sciences, Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia; Depar…
- Department of Medical Oncology, Grampians Health, Ballarat, Victoria, Australia; Department of Medical Oncology, Northern Health, Epping, Victoria, Australia; Department of Medical Oncology, Austin Health, Heidelberg, V…
Förderung
- Merck Sharp & Dohme (Australia) Pty Limited
- MSD
Zitieren
APA
Kim, G. Y., Wong, V., Loft, M., Lee, B., Wong, R., Chong, G., Jalali, A., Liew, M. S., Rainey, N., Burge, M., Hayes, T., Tebbutt, N. C., McLachlan, S. A., Mandaliya, H., Sutherland, S., Wong, S. F., Lim, S. H., Nott, L., Saqib, A., …, & Gibbs, P. (2026). Real-World Treatment and Outcomes for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer Following Pembrolizumab Availability in Australia. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2026.09.003
Vancouver
Kim GY, Wong V, Loft M, Lee B, Wong R, Chong G, et al. Real-World Treatment and Outcomes for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer Following Pembrolizumab Availability in Australia. Clinical Colorectal Cancer. 2026. doi:10.1016/j.clcc.2026.09.003
BibTeX
@article{Kim2026,
author = {Kim, Grace Y and Wong, Vanessa and Loft, Matthew and Lee, Belinda and Wong, Rachel and Chong, Geoff and Jalali, Azim and Liew, Mun Sem and Rainey, Natalie and Burge, Matthew and Hayes, Theresa and Tebbutt, Niall C and McLachlan, Sue-Anne and Mandaliya, Hiren and Sutherland, Sarah and Wong, Shu Fen and Lim, Stephanie H and Nott, Louise and Saqib, Ayesha and van Bavel, Julie and Bowers, Elani and Johns, Julie and Gibbs, Peter},
title = {Real-World Treatment and Outcomes for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer Following Pembrolizumab Availability in Australia},
journal = {Clinical Colorectal Cancer},
year = {2026},
doi = {10.1016/j.clcc.2026.09.003}
}
EUVIMED